Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticlePediatric Rheumatology

Achievement of a State of Inactive Disease at Least Once in the First 5 Years Predicts Better Outcome of Patients with Polyarticular Juvenile Idiopathic Arthritis

ALESSANDRA MAGNANI, ANGELA PISTORIO, SILVIA MAGNI-MANZONI, ALESSANDRA FALCONE, GIUSEPPINA LOMBARDINI, MARCIA BANDEIRA, FEDERICA ROSSI, ILARIA SALA, ALBERTO MARTINI and ANGELO RAVELLI
The Journal of Rheumatology March 2009, 36 (3) 628-634; DOI: https://doi.org/10.3899/jrheum.080560
ALESSANDRA MAGNANI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANGELA PISTORIO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SILVIA MAGNI-MANZONI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALESSANDRA FALCONE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GIUSEPPINA LOMBARDINI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARCIA BANDEIRA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FEDERICA ROSSI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ILARIA SALA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALBERTO MARTINI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANGELO RAVELLI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: angeloravelli@ospedale-gaslini.ge.it
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Median values (first and third quartiles) of the restricted joint count at last followup visit in patients who did not achieve (No ID), achieved only once (1 ID), or achieved 2 or more times (≥ 2 ID) the state of inactive disease in the first 5 years after first observation.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Median values (first and third quartiles) of the Juvenile Arthritis Damage Index (JADI)-Articular at last followup visit in patients who did not achieve (No ID), achieved only once (1 ID), or achieved 2 or more times (≥ 2 ID) the state of inactive disease in the first 5 years after first observation.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Median values (first and third quartiles) of the Childhood Health Assessment Questionnaire (CHAQ) disability index at last followup visit in patients who did not achieve (No ID), achieved only once (1 ID), or achieved 2 or more times (≥ 2 ID) the state of inactive disease in the first 5 years after first observation.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Median values (first and third quartiles) of the Poznanski score of radiographic damage at last followup visit in patients who did not achieve (No ID), achieved only once (1 ID), or achieved 2 or more times (≥ 2 ID) the state of inactive disease in the first 5 years after first observation.

Tables

  • Figures
    • View popup
    Table 1.

    Comparison of baseline clinical features between patients included and not included in the study. Values are medians (first and third quartiles) unless otherwise indicated.

    FeaturenPatients Included, n = 123nPatients Not Included, n = 114p
    No. (%) male/female12332 (26)/91 (74)11437 (32.5)/77 (67.5)0.28a
    ILAR category, n (%)†1231140.15a
      Extended oligoarthritis56 (45.5)45 (39.5)
      Polyarthritis, 5 rheumatoid factor-positive32 (26)43 (37.7)
      Systemic arthritis35 (28.5)26 (22.8)
    Age at disease onset, yrs1233.9 (2; 6.6)1143.4 (2; 6.5)0.58b
    Disease duration, yrs1230.6 (0.2; 1.8)1140.5 (0.2; 1.3)0.11b
    Physician’s global assessment*787.5 (5.3; 9.0)758.4 (7.3; 10)0.008b
    Parent’s global assessment*633.3 (1.6; 5.5)583.9 (1.2; 6.0)0.55b
    Parent’s pain assessment*493.4 (2.0; 6.0)403.4 (1.2; 5.5)0.72b
    Swollen joint count1184.0 (2.0: 9.0)1025.0 (3.0; 9.0)0.57b
    Tender joint count1183.5 (1.0; 8.0)1025.0 (2.0; 9.0)0.09b
    Restricted joint count1184.0 (1.0; 8.0)1025.0 (2.0; 8.0)0.21b
    Active joint count1185.0 (3.0; 12.0)1026.0 (3.0; 11.0)0.38b
    CHAQ disability index**860.6 (0.1; 1.0)750.7 (0.4; 1.2)0.10b
    ESR, mm/h; normal < 20 mm/h11845.0 (30.0; 75.0)10352.0 (32.0; 71.0)0.45b
    C-reactive protein, mg/dl††742.6 (0.6; 6.5)512.0 (0.6; 5)0.53b
    Poznanski score, units***64–0.8 (–1.5; 0.1)43–1 (–2; 0.3)0.54b
    • ILAR: International League of Associations of Rheumatology; CHAQ: Childhood Health Assessment Questionnaire; ESR: erythrocyte sedimentation rate.

    • ↵† For purposes of the analysis, patients with ILAR categories of psoriatic arthritis (n = 6) and undifferentiated arthritis (n = 7) were classified within polyarthritis and extended oligoarthritis categories based on the number of joints affected in the first 6 months of disease.

    • ↵a Chisquare test;

    • ↵b Mann-Whitney U test.

    • ↵* Range 0 (best) to 10 (worst);

    • ↵** range 0 (best) to 3 (worst);

    • ↵†† normal < 0.3 mg/dl;

    • ↵*** abnormal score < –2 units.

    • View popup
    Table 2.

    Baseline clinical features, followup duration, and antirheumatic medications among patients who achieved or did not achieve the state of inactive disease in the first 5 years after baseline. Values are medians (first and third quartiles) unless otherwise indicated.

    No Inactive Disease,1 Episode of Inactive Disease,≥ 2 Episodes of Inactive Disease,
    Featurenn = 62nn = 40nn = 21p
    No. (%) male/female6218 (29)/44 (71)409 (23)/31 (78)215 (24)/16 (76)0.74a
    ILAR category, n (%)6240210.16a
      Oligoarthritis extended23 (37.1)23 (57.5)10 (47.6)
       Polyarthritis17 (27.4)11 (27.5)4 (19)
       Systemic arthritis22 (35.5)6 (15)7 (33.3)
    Age at disease onset, yrs624.2 (2.1; 6.6)403.3 (2; 6.4)213.9 (1.9; 4.8)0.67c
    Disease duration, yrs620.8 (0.3; 1.8)390.4 (0.2; 1.5)210.6 (0.4; 1.9)0.40c
    Interval disease onset–first observation, yrs620.8 (0.4; 1.8)400.5 (0.2; 1.5)210.6 (0.4; 1.9)0.41c
    Interval first–last observation, yrs628.1 (6.8–10.5)407.0 (6.5–9.0)216.7 (6.4–7.4)0.06c
    Interval disease onset–methotrexate start, yrs622.1 (0.8; 4.2)402.1 (0.8; 4.8)211.3 (0.6; 3.0)0.25c
    Physician’s global assessment327.5 (7.5; 10)277.3 (4.6; 8.1)197.5 (6.1; 9.0)0.09c
    Parent’s global assessment223.0 (2.0; 6.9)233.3 (1.5; 6.3)184 (1.7; 5.5)0.83c
    Parent’s pain assessment135.0 (0.7; 6.0)213.4 (2.3; 6.5)153.3 (2.0; 5.0)0.97c
    Swollen joint count594.0 (2.0; 10.0)383.0 (2.0; 5.0)217.0 (4.0; 17.0)0.009*c
    Tender joint count593.0 (0.0; 9.0)382.5 (1.0; 5.0)216.0 (3.0; 16.0)0.02†c
    Restricted joint count594.0 (1.0; 9.0)383.5 (1.0; 6.0)216.0 (3.0; 8.0)0.17c
    Active joint count595.0 (3.0; 14.0)384.0 (2.0; 7.0)217.0 (5.0; 22.0)0.02††c
    CHAQ disability index390.6 (0.0; 1.0)280.5 (0.2; 1.1)190.8 (0; 1.3)0.59c
    Erythrocyte sedimentation rate, mm/h5950 (32; 77)3843.5 (25; 67)2137 (22; 56)0.27c
    C-reactive protein, mg/dl294.6 (0.6; 6.5)261.6 (0.7; 6.8)191.9 (0.4; 5.2)0.44c
    Poznanski score, units33–0.86 (–1.6; –0.1)18–0.8 (–1; 0.1)13–0.5 (–1.3; 0.1)0.75c
    Duration of methotrexate therapy, yrs**624.4 (3.6; 5.0)403.8 (3.1; 4.6)213.9 (3.2; 4.7)0.04***c
    No. (%) patients who received cyclosporine**6231 (50.0)4011 (27.5)213 (14.3)0.005†††a
    No. (%) patients who received sulfasalazine**6211 (17.7)407 (17.5)210 (0.0)0.09b
    No. (%) patients who received etanercept**6211 (17.7)407 (17.5)211 (4.8)0.37b
    No. (%) patients who received prednisone**6221 (33.9)409 (22.5)215 (23.8)0.40a
    • ILAR: International League of Associations of Rheumatology; CHAQ: Childhood Health Assessment Questionnaire. See Table 1 for score ranges of outcome measures.

    • ↵** In the first 5 years after first observation.

    • ↵a chi-squared test;

    • ↵b Fisher’s exact test;

    • ↵c Kruskal-Wallis test. Post-hoc comparisons:

    • ↵* swollen joint count is greater in patients with ≥ 2 episodes of inactive disease than in patients with 1 episode of inactive disease (Dunn’s test; p < 0.01);

    • ↵† tender joint count is greater in patients with ≥ 2 episodes of inactive disease than in patients with 1 episode of inactive disease (Dunn’s test; p < 0.05);

    • ↵†† active joint count is greater in patients with ≥ 2 episodes of inactive disease than in patients with 1 episode of inactive disease (Dunn’s test; p < 0.05);

    • ↵*** Dunn’s test not significant;

    • ↵††† frequency of cyclosporine therapy is greater in patients with no inactive disease than in patients with ≥ 2 episodes of inactive disease (chi-square with Bonferroni correction; p = 0.01).

    • View popup
    Table 3.

    Best-fitting models of logistic regression analysis.

    Outcome
    No Inactive Disease (n = 50/92; 54.3%) OR (95% CI)≥2 Episodes of Inactive Disease (n = 14/88; 15.9%) OR (95% CI)
    Cyclosporine therapy (yes/no)3.97 (1.57–10.06)**0.13 (0.03–0.65)**
    Duration of methotrexate therapy (>4/≤ 4 yrs)2.67 (1.08–6.62)*
    Swollen joint count at baseline (> 4/≤ 4)5.99 (1.45–24.77)**
    Area under ROC curve of the model0.720.77
    • Log-likelihood ratio test:

    • ↵* p < 0.05;

    • ↵** p < 0.01. ROC: receiver-operation characteristic.

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 36, Issue 3
1 Mar 2009
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Achievement of a State of Inactive Disease at Least Once in the First 5 Years Predicts Better Outcome of Patients with Polyarticular Juvenile Idiopathic Arthritis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Achievement of a State of Inactive Disease at Least Once in the First 5 Years Predicts Better Outcome of Patients with Polyarticular Juvenile Idiopathic Arthritis
ALESSANDRA MAGNANI, ANGELA PISTORIO, SILVIA MAGNI-MANZONI, ALESSANDRA FALCONE, GIUSEPPINA LOMBARDINI, MARCIA BANDEIRA, FEDERICA ROSSI, ILARIA SALA, ALBERTO MARTINI, ANGELO RAVELLI
The Journal of Rheumatology Mar 2009, 36 (3) 628-634; DOI: 10.3899/jrheum.080560

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Achievement of a State of Inactive Disease at Least Once in the First 5 Years Predicts Better Outcome of Patients with Polyarticular Juvenile Idiopathic Arthritis
ALESSANDRA MAGNANI, ANGELA PISTORIO, SILVIA MAGNI-MANZONI, ALESSANDRA FALCONE, GIUSEPPINA LOMBARDINI, MARCIA BANDEIRA, FEDERICA ROSSI, ILARIA SALA, ALBERTO MARTINI, ANGELO RAVELLI
The Journal of Rheumatology Mar 2009, 36 (3) 628-634; DOI: 10.3899/jrheum.080560
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Differentially Expressed Inflammation-Regulating MicroRNAs in Oligoarticular Juvenile Idiopathic Arthritis
  • Reliability of the Pediatric Specific Musculoskeletal Ultrasound Scoring Systems for the Elbow, Wrist, and Finger Joints
  • Patient-Reported Outcomes Among Transition-Age Young Adults With Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Show more Pediatric Rheumatology

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire